Assessing The Efficacy of Semaglutide on Glycaemia Control and Weight Reduction among Patients with Type 2 Diabetes at the Outpatient Department of Teaching Hospital
DOI:
https://doi.org/10.61561/ssbgjms.v6i01.76Keywords:
Semaglutide, Glycaemia, Type 2 Diabetes, Weight ReductionAbstract
Introduction: Type 2 diabetes is a growing global health concern, often requiring multifaceted treatment approaches to achieve optimal glycemic control and weight management. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in improving blood sugar levels. This study aims to assess the efficacy of Semaglutide in glycemic control and weight reduction among patients with Type 2 diabetes attending the outpatient department of a teaching hospital.
Methods: This study was conducted at the outpatient department of Green life teaching hospital from 1st July to 31st December 2024. A total of 31 patients were enrolled using a convenience sampling method. Data analysis was performed using SPSS version 26. Descriptive statistics were used to analyze patient characteristics, while chi-square tests were applied to determine the association between Semaglutide use and glycemic control, as well as weight reduction.
Findings: The study (n=31) had a high percentage of female participants (93.5%), most of whom were aged 18-39 years (64.5%). Semaglutide was used by 93.5% of participants, though 64.5% experienced side effects, the most frequent being nausea. The largest reported issue was cost (67.7%), but 83.9% lost weight. Diabetes knowledge was high, with 87.1% of participants valuing diet and exercise. Few experienced financial difficulties, and 71% resided <5 km from healthcare personnel. Semaglutide caused profound effects on glycemic control (+67.8%, p < 0.001) and weight loss (+67.8%, p < 0.001) and a highly significant positive correlation between the two responses (r = 0.62, p = 0.002).
Interpretation: Semaglutide has a strong association with glycemia control (p < 0.001, +67.8% improvement). It also has a strong association with weight reduction (p < 0.001, +67.8% weight loss). There is a significant correlation between glycemic control and weight loss (r = 0.62, p = 0.002). This statistical evidence confirms that Semaglutide is highly effective in improving both glycemic control and weight management among Type 2 Diabetes patients.
References
1. Magliano DJ, Boyko EJ, Atlas ID. What is diabetes? In: IDF DIABETES ATLAS [Internet] 10th edition [Internet]. International Diabetes Federation; 2021 [cited 2025 Mar 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581938/
2. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271–81.
3. Association AD. Standards of care in diabetes—2023 abridged for primary care providers. Clinical Diabetes. 2023;41(1):4–31.
4. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015;1(1):1–22.
5. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism. 2021;46:101102.
6. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311–22.
7. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism. 2018;27(4):740–56.
8. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The lancet Diabetes & endocrinology. 2017;5(5):341–54.
9. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes care. 2019;42(12):2272–81.
10. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989–1002.
11. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2020;43(2):487–93.
12. Butuca A, Dobrea CM, Arseniu AM, Frum A, Chis AA, Rus LL, et al. An assessment of semaglutide safety based on real world data: from popularity to spontaneous reporting in Eudravigilance database. Biomedicines. 2024;12(5):1124.
13. Polonsky W, Henry R. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. PPA. 2016 Jul;Volume 10:1299–307.
14. Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet Diabetes & endocrinology. 2018;6(4):275–86.
15. Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. The lancet Diabetes & endocrinology. 2019;7(7):528–39.
16. Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The lancet Diabetes & endocrinology. 2019;7(11):834–44.
17. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity Metabolism. 2022 Aug;24(8):1553–64.
18. Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. 2022 Mar;75(3):718–24.
19. Association AD. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes care. 2021;44(Supplement_1):S111–24.
20. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International journal of obesity. 2013;37(11):1443–51.
21. Camilleri M, Lupianez-Merly C. Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice. Official journal of the American College of Gastroenterology| ACG. 2022;10–14309.
22. Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. JMCP. 2022 Jul;28(7):740–52.
23. Hunt B, Hansen BB, Ericsson Å, Kallenbach K, Ali SN, Dang-Tan T, et al. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Adv Ther. 2019 Dec;36(12):3483–93.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
